Study for Treatment of Moderate or Severe, Periodic, Cyclic, Breast Pain
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of IoGen™ for the Treatment of Moderate or Severe, Periodic Breast Pain Associated With Symptomatic Fibrocystic Breast Disease
Sponsor: Symbollon Pharmaceuticals
A PHASE3 clinical study on Fibrocystic Changes of Breast and Fibrocystic Disease of Breast, this trial is ongoing. The trial is conducted by Symbollon Pharmaceuticals and has accumulated 6 data snapshots since 2005. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
6 versions recorded-
Sep 2025 — Present [monthly]
Unknown PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Unknown PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE3
Status: Unknown Status → Unknown
-
Jan 2021 — Jul 2024 [monthly]
Unknown Status PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Unknown Status PHASE3
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Unknown Status PHASE3
First recorded
Jul 2005
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Symbollon Pharmaceuticals
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Boynton Beach, United States , Champaign, United States , Cincinnati, United States , Clearwater, United States , Colorado Springs, United States , Decatur, United States , Denver, United States , Hartford, United States , Hershey, United States , Hilton Head Island, United States and 28 more locations